Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R15.htm
EX-32.1 - EXHIBIT 32.1 - MedClean Technologies, Inc.v314039_32-1.htm
EX-31.2 - EXHIBIT 31.2 - MedClean Technologies, Inc.v314039_31-2.htm
EX-31.1 - EXHIBIT 31.1 - MedClean Technologies, Inc.v314039_31-1.htm
XML - IDEA: XBRL DOCUMENT - MedClean Technologies, Inc.R6.htm
EX-32.2 - EXHIBIT 32.2 - MedClean Technologies, Inc.v314039_32-2.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: March 31, 2012

 

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number: 000-03125

 

MEDCLEAN TECHNOLOGIES, INC.

(Exact Name of registrant as specified in its charter)

 

Delaware 21-0661726
(State or other Jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)

 

310 Stoke Park Road

Bethlehem, Pennsylvania 18017

(Address of principal executive offices)

 

(203) 798-1080

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). 

Yes ¨   No x

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act:

 

¨ Large Accelerated Filer ¨ Accelerated Filer
       
¨ Non-Accelerated Filer x Smaller Reporting Company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨   No x

 

As of May 21, 2012, there were 2,307,311,187 shares outstanding of the registrant’s common stock.

 

 
 

 

TABLE OF CONTENTS

 

    Page  
PART I — FINANCIAL INFORMATION  
         
Item 1. Financial Statements.     3  
         
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.     4  
         
Item 3. Quantitative and Qualitative disclosures about Market Risk.     6  
         
Item 4. Controls and Procedures.     6  
         
PART II - OTHER INFORMATION  
         
Item 1. Legal Proceedings.     7  
         
Item 1A. Risk Factors.     7  
         
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.     7  
         
Item 3. Defaults Upon Senior Securities.     7  
         
Item 4. Mining Safety Disclosures.     7  
         
Item 5. Other Information.     7  
         
Item 6. Exhibits.     8  
         
Signatures     9  

 

2
 

 

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

INDEX TO FINANCIAL STATEMENTS

 

    PAGE  
       
   CONDENSED BALANCE SHEETS AS OF MARCH 31, 2012 (UNAUDITED) AND DECEMBER 31, 2011     F-1  
         
   UNAUDITED CONDENSED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011 (RESTATED)     F-2  
         
   UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011 (RESTATED)     F-3  
         
NOTES TO UNAUDITED FINANCIAL STATEMENTS     F-4  

 

3
 

 

MEDCLEAN TECHNOLOGIES, INC.

CONDENSED BALANCE SHEETS

 

   March 31,   December 31, 
   2012   2011 
   (unaudited)     
ASSETS          
Current assets          
Cash  $12,914   $26,009 
Accounts receivable, net   95,057    170,585 
Revenues in excess of billings   7,679    7,679 
Inventory   210,944    243,685 
Prepaid expenses   35,247    26,627 
Total current assets:   361,841    474,585 
           
Property, plant and equipment, net   13,989    15,951 
           
Other assets:          
Long term inventory   158,993    158,993 
Deposits   6,368    6,368 
           
Total assets  $541,191   $655,897 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
Current liabilities          
Accounts payable and accrued liabilities  $426,685   $432,000 
Payroll liabilities   99,614    48,157 
Accrued liabilities, related party   520,704    517,342 
Deferred revenue   528,722    505,189 
Billings in excess of revenue   51,332    51,332 
Notes payable   240,972    238,047 
Total current liabilities:   1,868,029    1,792,067 
           
Long term debt:          
Derivative liability   116,186    127,021 
Convertible notes, net of debt discount of $140,439 and $207,791   55,631    54,009 
Total liabilities   2,039,846    1,973,097 
           
Stockholders' deficit          
Preferred stock, $0.0001 par value, 60,000,000 shares authorized, none issued outstanding          
Common stock, $0.0001 par value; 3,500,000,000 shares authorized; 2,069,961,886 and 1,640,311,420 shares issued and outstanding as of March 31, 2012 and December 31, 2011, respectively   206,996    164,031 
Additional paid in capital   32,950,398    32,775,738 
Accumulated deficit   (34,656,049)   (34,256,969)
Total stockholders' deficit:   (1,498,655)   (1,317,200)
           
Total liabilities and stockholders' deficit  $541,191   $655,897 

 

See the accompanying notes to these unaudited condensed financial statements

 

F-1
 

 

MEDCLEAN TECHNOLOGIES, INC.

CONDENSED STATEMENTS OF OPERATIONS

 

   Three months ended March 31, 
   2012   2011 
       (restated) 
Revenues          
Contract revenue earned  $-   $450,000 
Sales and service revenues   116,122    143,624 
Total revenues   116,122    593,624 
           
Cost of sales          
Contract cost of sales   -    230,934 
Sales and service cost of sales   61,139    74,982 
Total cost of sales   61,139    305,916 
           
Gross profit   54,983    287,708 
           
Operating expenses          
Salaries and wages   160,957    562,239 
General and administrative expenses   141,409    358,407 
Depreciation   1,622    21,040 
Total operating expenses   303,988    941,686 
           
Loss from operations   (249,005)   (653,978)
           
Other income and expenses          
Interest and other income   -    88 
Loss on change in fair value of derivatives   (56,835)   (189,165)
Interest expense   (93,240)   (697,708)
           
Net Loss before income taxes   (399,080)   (1,540,763)
           
Provision for income taxes (benefit)   -    - 
           
Net Loss  $(399,080)  $(1,540,763)
           
Loss per common share, basic and diluted  $(0.00)  $(0.00)
           
Weighted average common shares outstanding, basic and diluted   1,788,086,439    1,129,306,013 

 

See the accompanying notes to these unaudited condensed financial statements

 

F-2
 

 

MEDCLEAN TECHNOLOGIES, INC.

CONDENSED STATEMENTS OF CASH FLOWS

 

   Three months ended March 31, 
   2012   2011 
       (restated) 
Cash flows from operating activities:          
Net loss  $(399,080)  $(1,540,763)
Adjustments to reconcile net loss to net cash used in operating activities          
Depreciation   1,962    22,344 
Amortization of debt discount   86,952    469,681 
Fair value of common stock, options and warrants issued for services rendered   4,625    352,733 
Non cash interest expense relating to convertible debt   -    225,102 
Loss on change in fair value of derivative liability   56,835    189,165 
(Increase) decrease in:          
Accounts receivable   75,528    98,673 
Inventory   32,741    84,319 
Prepaid expenses and other   (8,620)   (1,806)
Increase (decrease) in:          
Accounts payable   972    66,094 
Payroll liabilities   51,457    (19,356)
Deferred revenue   23,533    212,943 
Net cash provided by (used in) operating activities   (73,095)   159,129 
           
Cash flows from investing activities:          
Purchase of equipment   -    (9,695)
Net cash used in investing activities   -    (9,695)
           
Cash flows from financing activities:          
Proceeds from issuance of put agreements   60,000    125,000 
Proceeds from issuance of convertible notes   -    380,000 
Net cash provided by financing activities   60,000    505,000 
           
(Decrease) increase in cash and cash equivalents   (13,095)   654,434 
           
Cash and cash equivalents, beginning of period   26,009    182,046 
           
Cash and cash equivalents, end of period  $12,914   $836,480 
           
Supplemental disclosures of cash flow information:          
Cash paid during the period for:          
Interest  $-   $1,198 
Taxes  $-   $- 
           
Non cash financing activities:          
Common stock issued in settlement of convertible notes  $153,000   $499,545 

 

See the accompanying notes to these unaudited condensed financial statements

 

F-3
 

 

MEDCLEAN TECHNOLOGIES, INC.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2012

 

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

A summary of the significant accounting policies applied in the presentation of the accompanying financial statements is as follows:

 

General

 

The accompanying unaudited condensed financial statements of MedClean Technologies, Inc. (“MedClean,” the “Company” or “MCLN”), have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

 

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.  Accordingly, the results from operations for the three-month period ended March 31, 2012, are not necessarily indicative of the results that may be expected for the year ending December 31, 2012.  The unaudited condensed financial statements should be read in conjunction with the December 31, 2011, financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2012.

 

The financial statements as of December 31, 2011, have been derived from the audited financial statements at that date but do not include all disclosures required by the accounting principles generally accepted in the United States of America.

 

Business and Basis of Presentation

 

The Company was originally incorporated in the State of Delaware under the name General Devices, Inc.  Effective January 23, 2006, the Company merged (the “Merger”) with Aduromed Industries, Inc. (“Aduromed”), whereby Aduromed became the wholly-owned subsidiary of the Company and the former holders of the equity in Aduromed became holders of equity in the Company.  Effective January 30, 2007, the Company changed its corporate name from General Devices, Inc. to Aduromed Industries, Inc.

 

Effective January 2, 2009, the Company changed its corporate name from Aduromed to MedClean Technologies, Inc.  Also effective January 2, 2009, the Company merged its former wholly-owned subsidiary, Aduromed Corporation, with and into the Company.

 

MedClean is in the business of providing solutions for managing medical waste on site, including designing, selling, installing and servicing on site (i.e. “in-situ”) turnkey systems to treat regulated medical waste.  The Company provides these systems to hospitals and other medical facilities as efficient, safe, cost effective and legally compliant solutions to incineration, off site hauling of untreated waste and other alternative treatment technologies and methodologies.  The MedClean Series System is offered in three configurations: Containerized System, Mobile System and the Fixed System (our traditional fixed installation).

 

F-4
 

 

MEDCLEAN TECHNOLOGIES, INC.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2012

 

Accounts Receivable

 

The Company assesses the realization of its receivables by performing ongoing credit evaluations of its customers’ financial condition.  Through these evaluations, the Company may become aware of a situation where a customer may not be able to meet its financial obligations due to deterioration of its financial viability, credit ratings or bankruptcy.  The Company’s reserve requirements are based on the best facts available to the Company and are reevaluated and adjusted as additional information is received.  The Company’s reserves are also based on amounts determined by using percentages applied to certain aged receivable categories.  These percentages are determined by a variety of factors including, but not limited to, current economic trends, historical payment and bad debt write-off experience.  Allowance for doubtful accounts for accounts and notes receivable was $24,097 as of March 31, 2012 and December 31, 2011, respectively.

 

Revenue recognition

 

The Company’s revenue recognition policy is in accordance with the requirements of Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition, (“SAB 104”), ASC Topic 605, Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products) and other applicable revenue recognition guidance and interpretations.  System revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured.

 

Deferred Revenues consist of cash received in advance for goods to be delivered at a future date.  The Company records the payments received from customers as a liability until the products are delivered.  Sales are recorded when the products are delivered.

 

Contract costs include all direct material and labor costs and those indirect costs related to contract performance.  Selling, general and administrative costs are charged to expense as incurred.  Provisions for estimated losses on uncompleted contracts are made in the period in which such losses are determined.  Changes in job performance, job conditions and estimated profitability may result in revisions to costs and income, which are recognized in the period in which the revisions are determined.  Changes in estimated job profitability resulting from job performance, job conditions, contract penalty provisions, claims, change orders and settlements, are accounted for as changes in estimates in the current period.

 

The Company provides a one-year warranty on the systems it installs.  The Company also obtains a one-year warranty on the system components from the component manufacturer, thereby mitigating potential warranty costs.  Accordingly, the Company has accrued no reserve for warranty.  On the installed base after the warranty term has expired, the Company offers a maintenance agreement of one or more years to the customer.  The customer is billed for and pays for the maintenance agreement in advance.  Revenues from such maintenance agreements are recognized ratably over the lives of the maintenance agreements, with the excess of the amount collected over the amount recognized as deferred revenue.  At March 31, 2012 and December 31, 2011, the Company had $528,722 and $505,189, respectively, in deferred revenue from system installs and maintenance agreements.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

 

The Company maintains cash deposits with financial institutions, which from time to time may exceed federally insured limits.  The Company has not experienced any losses and believes it is not exposed to any significant credit risk from cash.  

 

F-5
 

 

MEDCLEAN TECHNOLOGIES, INC.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2012

 

Estimates

 

The preparation of the accompanying financial statements, in conformity with generally accepted accounting principles, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods.  Actual results could differ from those estimates.

 

Reclassification

 

Certain reclassifications have been made to prior periods’ data to conform to the current year’s presentation.  These reclassifications had no effect on reported income or losses.

 

Segment information

 

Accounting Standards Codification (“ASC”) establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders.  ASC also establishes standards for related disclosures about products and services and geographic areas.  Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance.  The Company applies the management approach to the identification of our reportable operating segment as provided in accordance with ASC.  The information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment.

 

Dependence on principal customer

 

For 2012 and going forward, the Company does not anticipate that the loss of any one customer will have a significant adverse impact on the Company’s business.

 

Fair value of financial instruments

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2012 and December 31, 2011.  The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash and accounts payable.  Fair values were assumed to approximate carrying values for cash and payables because they are short term in nature and their carrying amounts approximate fair values or they are payable on demand.

 

As described in Note 9, items recorded or measured at fair value on a recurring basis in the accompanying financial statements consisted of the debt derivative liabilities.

 

Stock based compensation

 

The Company has adopted ASC subtopic 718-10, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values.

 

As more fully described in Note 11 below, the Company granted equity based compensation over the years to employees of the Company under its equity plans.  The Company granted non-qualified stock options to purchase 17,500,000 and 17,500,000 shares of common stock during the three-month period ended March 31, 2012 and 2011, respectively, to employees and directors of the Company.

 

F-6
 

 

MEDCLEAN TECHNOLOGIES, INC.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2012

 

Inventory

 

The Company maintains an inventory, which consists primarily of component parts, spare parts and disposable goods.  The average cost method is utilized in valuing the inventory, and is stated at the lower of cost or market.  The following table summarizes these assets as of March 31, 2012 and December 31, 2011:

 

   March 31,
2012
   December 31,
2011
 
Component & spare parts  $348,863   $374,553 
Consumables   12,097    19,168 
Advance payments   8,977    8,977 
Total inventory   369,937    402,678 
Less current portion   210,944    243,685 
Inventory, long term portion  $158,993   $158,993 

 

Property, plant and equipment

 

The Company has property, plant and equipment that consist of computers and related accessories, and office furniture.  The depreciation is calculated using the straight line method over the life of the property.  All property has a useful life of 3 to 10 years.  The following table summarizes these assets as of March 31, 2012 and December 31, 2011:

 

   March 31,
2012
   December 31,
2011
 
Office Furniture  $15,783   $15,783 
Computers and Accessories   13,307    13,307 
Leasehold Improvements   9,425    9,425 
    38,515    38,515 
Accumulated Depreciation   24,526    22,564 
   $13,989   $15,951 

 

During the three -month periods ended March 31, 2012 and 2011, depreciation expense charged to operations was $1,962 and $22,344, respectively, of which $340 and $1,303 was included as part of cost of goods sold, respectively.

 

Earnings (loss) per common share

 

The net earnings (loss) per common share are computed by dividing the net loss for the period by the weighted average number of shares outstanding for the period.  Shares issued upon conversion of convertible debt, outstanding warrants and options for the three month period ended March 31, 2012 amounting to 1,260,507,143 were not included in the calculation for net loss per common share because their effects would be anti-dilutive.

 

The numerator and denominator used in the basic and diluted earnings (loss) per share of common stock computations are presented in the following table:

 

F-7
 

 

MEDCLEAN TECHNOLOGIES, INC.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2012

 

   Three months ended
March 31,
 
   2012   2011 
NUMERATOR FOR BASIC AND DILUTED EPS (LPS)          
Net loss per statement of operations  $(417,652)  $(1,540,763)
           
DENOMINATOR FOR BASIC AND DILUTED EPS (LPS)          
Weighted average shares of common stock outstanding   1,788,086,439    1,129,306,013 
           
Basic and diluted EPS (LPS)  $(0.00)  $(0.00)

 

Recent Accounting Pronouncements

 

There were various updates recently issued by the Financial Accounting Standards Board, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's consolidated financial position, results of operations or cash flows.

 

NOTE 2 - GOING CONCERN MATTERS

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.  The Company has incurred substantial recurring losses, which raises substantial doubt about its ability to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The Company has available cash and cash equivalents of approximately $12,914 at March 31, 2012, which it intends to utilize for working capital purposes and to continue developing its business.  To supplement its cash resources, the Company has secured alternative financing arrangements with two investment entities.  While the acquisition of cash through these programs is related to company performance, we believe we will have access to the necessary funds for us to execute our business plan.  However, we continue to incur significant operating losses that will result in the reduction of our cash position.  We cannot assure that we will be able to continue to obtain funding through the alternative financing arrangements and the lack thereof would have a material adverse impact on our business.  Moreover, any equity funding could be substantially dilutive to existing stockholders.  The aforementioned factors raise substantial doubt about our ability to continue as a going concern.  In the event the Company is unable to continue as a going concern, it may pursue a number of different options, including, but not limited to, filing for protection under the federal bankruptcy code.

 

NOTE 3 – RESTATEMENTS

 

During 2011, in connection with the issuance of convertible notes, the Company had originally recorded the conversion option embedded feature as an equity (beneficial conversion feature) instrument.  Subsequently, the Company determined that there is a possibility of exceeding their common shares authorized when considering the number of possible shares that may be issuable to satisfy settlement provisions of these agreements after consideration of all existing instruments that could be settled in shares.  As such, these restatements reflect the correction in accounting and to properly record the related derivative liability:

 

F-8
 

 

MEDCLEAN TECHNOLOGIES, INC.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
MARCH 31, 2012
 

 

Condensed Statement of Operations

Three months ended March 31, 2011

 

    Previously                
    Reported     Adjustment   Ref   Restated  
Revenues   $ 593,624     $ -       $ 593,624  
Cost of sales     305,916       -         305,916  
Gross profit     287,708                 287,708  
                           
Operating expenses (unchanged)     941,686       -         941,686  
                           
Net loss from operations     (653,978 )     -         (653,978 )
                           
Other income (expense)                          
Interest and other income     88       -         88  
Gain on change in fair value of derivative     -       (189,165 (a)     (189,165
Interest expense     (472,606 )     (225,102 (b)     (697,708 )
                           
Net Loss   $ (1,126,496 )   $ (414,267     $ (1,540,763 )
                           
 Loss per common stock, basic and diluted   $ (0.00 )   $ (0.00 )     $ (0.00 )
                           
Weighted average number of shares outstanding, basic and diluted     1,129,306,013       1,129,306,013         1,129,306,013  

 

(a)   Mark to market adjustment of the derivative liability
(b) Interest expense relating to derivative features underlying convertible notes

 

Condensed Statement of Cash Flows

Three months ended March 31, 2011

 

    Previously                
    Reported     Adjustment   REF   Restated  
Net loss   $ (1,126,496 )   $ (414,267 )  (a),(b)   $ (1,540,763 )
Gain on change in fair value of derivative liability     -       189,165   (a)     189,165  
Non cash interest expense relating to convertible debt     -       225,102   (b)     225,102  
Other operating activities (unchanged)     1,285,625       -         1,285,625  
Net cash provided by operating activities     159,129       -         159,129  
                           
Net cash used in investing activities (unchanged)     (9,695 )     -         (9,695 )
                           
Net cash provided by financing activities (unchanged)     505,000       -         505,000  
                           
Net increase in cash     654,434       -         654,434  
                           
Cash, beginning of period     182,046       -         182,046  
                           
Cash, end of period   $ 836,480     $ -       $ 836,480  

 (a)   Mark to market adjustment of the derivative liability
 (b)   Interest expense relating to derivative features underlying convertible notes

 

F-9
 

 

MEDCLEAN TECHNOLOGIES, INC.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
MARCH 31, 2012
 

 

 NOTE 4 – BACKLOG AND CONTRACTS IN PROCESS

 

Backlog at March 31, 2012, was $1,047,100, compared to $1,047,100 at December 31, 2011.  Once work commences, revenue is recognized upon delivery of the system or completion of the work.  Prior to 2009, revenue was recognized on a percentage of completion basis.  The Company has one remaining contract in which revenue will be recognized in this manner.  The outstanding backlog value of the percentage of completion contracts is $151,255.  The following table summarizes the percentage of completion of the Company's outstanding contracts:

 

Contract   Revenue       Amounts   Revenues in   Billings in excess 
Amount   Recognized   Backlog   Billed   excess of Billings   of Revenues 
Outstanding contracts at March 31, 2012
         
                      
$315,194   $163,939   $151,255   $215,271   $7,679   $51,332 
                            
 Outstanding contracts at December 31, 2011                
                            
$315,194   $163,939   $151,255   $215,271   $7,679   $51,332 

 

 NOTE 5 – SHORT TERM NOTE PAYABLE

 

The Company’s outstanding unsecured note bears a 12% interest rate and matured on December 15, 2003.  Both parties have entered a verbal agreement to extend the maturity date on this note indefinitely.  No accrued interest has been paid on this note to date.  As of March 31, 2012 and December 31, 2011, the balance due was $240,972 and $238,047, respectively.

 

NOTE 6 – RELATED PARTY TRANSACTIONS

 

During 2011 and 2010, the Company had a consulting agreement with a former board member for corporate strategy and finance services.  The current agreement terminated on July 31, 2011.  During the three month period ended March 31, 2012 and 2011, the Company paid $-0- and $-0-, respectively.  At March 31, 2012 and December 31, 2011, the Company accrued $-0- and $72,000, respectively. As of March 31, 2012 and December 31, 2011, the balance due was $274,450 and 272,617, respectively.

 

In 2009, the Company accrued salary expense and provided a severance package for the former Chief Executive Officer and current board member.  The balance due at March 31, 2012 and December 31, 2011 was $246,255 and $244,725, respectively.

 

NOTE 7 – LINE OF CREDIT

 

On August 5, 2010, the Company and Southridge Partners II, LP (“Southridge”) entered into an Equity Credit Agreement (the “Agreement”).  Pursuant to the Agreement, Southridge has agreed to provide the Company with up to $15,000,000 of funding during the 36-month period following the date a registration statement of the Company’s common stock is declared effective by the SEC (the “Equity Line”).  During this 36-month period, commencing on the date on which the SEC first declares effective our registration statement, the Company may request a draw down under the Equity Line by which the Company would sell shares of its common stock to Southridge, which is obligated to purchase the shares under the Agreement.  For each share of our common stock purchased under the Agreement, Southridge will pay ninety-five percent (95%) of the average of the lowest closing bid price of our common stock reported by Bloomberg, LP in any two trading days, consecutive or inconsecutive, of the five consecutive trading day period (the "Valuation Period") commencing the date a put notice (the "Put Notice") is delivered to Southridge in a manner provided by the Agreement. Subject to certain limitations and floor price reductions, the Company may, at its sole discretion, issue a Put Notice to Southridge and Southridge will then be irrevocably bound to acquire such shares. The registration statement relating to the requested bond of the Company's common stock pursuant to the Agreement was declared effective on May 19, 2011 (File No. 333-174136).

 

F-10
 

 

MEDCLEAN TECHNOLOGIES, INC.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
MARCH 31, 2012
 

 

During the three months ended March 31, 2012, the Company “put” 95,650,023 shares of common stock to Southridge for a total of $60,000.

 

NOTE 8 – CONVERTIBLE NOTES

 

On October 7, 2010, the Company issued a $600,000 Convertible Promissory Note (“Convertible Note 1”) that matures October 6, 2013, in exchange for a promissory note receivable.  Convertible Note 1 bears a onetime interest charge at a rate of 6% per annum and will be convertible into Company’s common stock at any time at a conversion rate equal to the higher of (a) 70% of the lowest closing price during the 20 trading days previous to the conversion or (b) par value of the Company’s common stock.

 

For presentation purposes, the Company offset the unpaid promissory note receivable against the carrying value of the Convertible Note 1.

 

The Company analyzed the conversion feature in accordance with Accounting Standards Codification subtopic 815-15 (“ASC 815-15”), Embedded Derivatives, and 815-40, Contracts in Entity’s Own Equity (“ASC 815-40’), and determined that upon issuance of Convertible Note 1, based on the terms of the underlying conversion feature, the Company could be required to issue shares in excess of the authorized share limit and therefore the embedded derivative must be bifurcated from the host contract and measured at fair value the extent that the conversion option would be classified as a liability as a standalone instrument.  The Company had more than one contract that could be subject to this treatment and could result in partial reclassification out of equity, and the Company chose the method of reclassification of contracts with the earliest inception date first.

 

The Company received aggregate net proceeds of 318,000 from October 14, 2010 through March 31, 2012,  under the promissory notes receivable underlying Convertible Note 1. The derivative conversion feature underlying the advances under Convertible Note 1 was bifurcated and recorded at fair value of $412,721 with a discount against the principal of the related convertible notes and the remainder to interest expense. The debt discount attributed to this derivative conversion feature is being charged to income as interest expense ratably over the term of the notes.

 

For the three months ended March 31, 2012, the Company amortized and wrote off the debt discount noted above and charged $84,310 to interest expense.

 

On April 8, 2011, the Company issued a $600,000 Convertible Promissory Note (“Convertible Note 2”) that matures October 8, 2014, in exchange for a promissory note receivable.  Convertible Note 2 was issued under the same terms as the convertible note above.

 

The Company received aggregate net proceeds of 25,000 from May 31, 2011 through March 31, 2012,  under the promissory notes receivable underlying Convertible Note 2). The derivative conversion feature underlying these advances under Convertible Note 2 was bifurcated and recorded at fair value of $25,000 with a discount against the principal of the related Convertible Notes.

 

For the three months ended March 31, 2012, the Company amortized the debt discount noted above and charged $2,642 to interest expense.

 

The liability for these derivative conversion features was re-measured at fair value upon each reporting period. The changes in fair value resulted in a loss of $75,407 and $189,165 for the three months ended March 31, 2012 and 2011. The ending value as of March 31, 2012 was $134,758.

 

During the three months ended March 31, 2012, the Company issued an aggregate of 334,000,000 shares of its common stock in payment of $85,330 towards the note.

 

F-11
 

 

MEDCLEAN TECHNOLOGIES, INC.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
MARCH 31, 2012
 

 

NOTE 9 – DERIVATIVE LIABILITY

 

During 2010, in connection with the issuance of convertible notes, the Company has the possibility of exceeding their common shares authorized when considering the number of possible shares that may be issuable to satisfy settlement provisions of these agreements after consideration of all existing instruments that could be settled in shares.  The accounting treatment of derivative financial instruments required that the Company reclassify the derivative from equity to a liability at their fair values as of the date possible issuable shares exceeded the authorized level and at fair value as of each subsequent balance sheet date.  Any change in fair value was recorded as non-operating, non-cash income or expense at each reporting date.  If the fair value of the derivatives was higher at the subsequent balance sheet date, the Company recorded a non-operating, non-cash charge.  If the fair value of the derivatives was lower at the subsequent balance sheet date, the Company recorded non-operating, non-cash income.

 

The fair value of the derivative at March 31, 2012 was determined using the Black Sholes Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 243.43%; risk free rate: 0.33%; and expected life: 2.25 years.

 

Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.  

 

At March 31, 2012, the derivative liability valued at $116,186, the Company believes an event under the contract that would create an obligation to settle in cash or other current assets is remote and has classified the obligation as a long term liability.

 

NOTE 10 – CAPITAL STOCK

 

The Company is authorized to issue 3,500,000,000 shares of common stock, par value $0.0001 per share.  In addition, the Company is authorized to issue 60,000,000 shares of preferred stock, par value $0.0001 per share.

 

As of March 31, 2012 and December 31, 2011, the Company had 2,069,961,886 and 1,640,311,420 shares of common stock issued and outstanding, respectively, and no shares of preferred stock issued and outstanding, respectively.

 

NOTE 11 – WARRANTS AND OPTIONS

 

Warrants

 

The following table summarizes the changes in warrants outstanding and related prices for the shares of the Company’s common stock at March 31, 2012:

 

F-12
 

 

MEDCLEAN TECHNOLOGIES, INC.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
MARCH 31, 2012

 

Exercise Price   Number
Outstanding
   Warrants
Outstanding
Weighted
Average
Remaining
Contractual Life
(years)
   Weighted
Average
Exercise price
   Number
Exercisable
   Warrants
Exercisable
Weighted
Average
Exercise Price
 
$0.0040    16,000,000    1.33   $0.0040    16,000,000   $0.0040 
 0.0041    2,000,000    2.11    0.0041    2,000,000    0.0041 
 0.0075    69,530,574    1.34    0.0075    69,530,574    0.0075 
 0.0250    28,000,000    1.34    0.0250    28,000,000    0.0250 
 0.0900    600,000    0.96    0.0900    600,000    0.0900 
 0.2400    100,000    0.24    0.2400    100,000    0.2400 
 Total     116,230,574    1.27   $0.0189    116,230,574   $0.0119 

  

Transactions involving the Company’s warrant issuance are summarized as follows:

  

   Number of
Shares
   Weighted
Average
Price Per
Share
 
Outstanding at December 31, 2010   116,434,960   $0.0189 
Granted   2,000,000    0.0041 
Exercised   -    - 
Canceled or expired   (2,204,386)   (0.3788)
Outstanding at December 31, 2011   116,230,574    0.0119 
Granted   -    - 
Exercised   -    - 
Canceled or expired   -    - 
Outstanding at March 31, 2012   116,230,574   $0.0119 

 

Stock options

 

The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to employees and directors of the Company at March 31, 2012:

 

    Options Outstanding       Options Exercisable 
Exercise Prices   Number
Outstanding
   Weighted Average
Remaining
Contractual Life
(Years)
   Weighted
Average
Exercise Price
   Number
Exercisable
   Weighted
Average
Exercise Price
 
$0.00050    17,500,000    4.76   $0.00050    -   $0.00050 
$0.00346    13,750,000    4.97   $0.00346    10,625,000   $0.00346 
$0.00348    3,333,333    4.88   $0.00348    3,333,333   $0.00348 
$0.00400    538,868,937    3.13   $0.00400    538,868,937   $0.00400 
$0.00844    80,883,534    4.61   $0.00844    53,922,356   $0.00844 
$0.00232    2,083,000    4.84         2,083,000    0.00232 
$0.02500    2,000,000    2.33   $0.02500    2,000,000   $0.02500 
$0.02800    22,500,000    3.79   $0.02800    22,500,000   $0.02800 
Total     680,918,834    3.42   $0.00540    633,332,626   $0.00528 

 

F-13
 

 

MEDCLEAN TECHNOLOGIES, INC.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
MARCH 31, 2012
 

 

Transactions involving stock options issued to employees are summarized as follows:

 

       Weighted
Average
 
   Number of   Price 
   Shares   Per Share 
Outstanding at December 31, 2010:   644,502,168   $0.004 
Granted   22,916,666    0.034 
Exercised   (50,000)   (0.0034)
Canceled or expired   (3,950,000)   (0.346)
Outstanding at December 31, 2011:   663,418,834   $0.0054 
Granted   17,500,000    0.0005 
Exercised   -    - 
Canceled or expired   -    - 
Outstanding at March 31, 2012:   680,918,834   $0.00540 

 

On January 9, 2012, the Company granted options to purchase 17,500,000 shares of the Company’s common stock to directors valued at $8,578.  The option grants as approved by the Compensation Committee are vesting at 25% per quarterly, fully vested in one year and the exercise price is $0.0005 per share for five years.

 

The fair value for these awards was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions, assuming no expected dividends:

 

Expected life (years)   5 
Expected volatility   207.88%
Risk-free interest rate   0.85%
Dividend yield   %

  

NOTE 12 – FAIR VALUE MEASUREMENT

 

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008.  ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.  ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

 

· Level 1 - Quoted prices in active markets for identical assets or liabilities.

 

· Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

 

· Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

 

F-14
 

 

MEDCLEAN TECHNOLOGIES, INC.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
MARCH 31, 2012
 

 

 To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

 

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the consolidated financial statements.

 

The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (Including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.

 

Items recorded or measured at fair value on a recurring basis in the accompanying consolidated financial statements consisted of the debt derivative liabilities. Convertible notes were determined at market based on their short term historical conversions

 

   Quoted
Prices in
Active
Markets for
Identical
Instruments
Level 1
   Significant
Other
Observable
Inputs
Level 2
   Significant
Unobservable
Inputs
Level 3
   Assets (Liabilities)
At Fair Value
 
Liabilities:                    
Derivative liability  $-   $-   $(116,186)  $(116,186)
                     
Total  $-   $-   $(116,186)  $(116,186)

 

The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2012:

 

   Derivative
Liability
 
Balance, December 31, 2011  $127,021 
      
Mark-to-market at March 31, 2012:     
    Embedded debt derivative   56,835 
      
Reductions from conversions of debt   (67,670)
Balance, March 31, 2012  $116,186 

 

NOTE 13 – SUBSEQUENT EVENTS

 

Subsequent events have been evaluated through the date that the financial statements were issued and determined no reportable event occurred.

 

F-15
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward Looking Statements

 

This quarterly report on Form 10-Q and other reports filed by the Company from time to time with the SEC contain or may contain forward-looking statements (collectively the “Filings”) and information that are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by Company’s management.  Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof.  When used in the Filings, the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan”, or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements.  Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed with the SEC on May 15, 2012, relating to the Company’s industry, the Company’s operations and results of operations, and any businesses that the Company may acquire.  Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

 

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements.  Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”).  These accounting principles require us to make certain estimates, judgments and assumptions.  We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made.  These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented.  Our financial statements would be affected to the extent there are material differences between these estimates and actual results.  In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require management’s judgment in its application.  There are also areas in which management’s judgment in selecting any available alternative would not produce a materially different result.  The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.

 

Results of Operations

 

Three Months Ended March 31, 2012 Compared to Three Months Ended March 31, 2011

 

Net Revenue

 

Total revenue for the quarter ended March 31, 2012 was $116,122, compared with $593,624 for the same period in 2011, a decrease of $477,502 or 80.4%.

 

System revenues during the three month ended March 31, 2011, was $450,000, compared to $-0- in 2012.  The decrease in system revenue was the result of the installation of a fixed based system during the three months ended March 31, 2011 compared to none for 2012.  Revenues derived from the sale of consumables, component parts, service billings and amortization of maintenance contracts decreased by $27,502 or 19.1% in the current period to $116,122.  The decrease in service billings was a result of fewer service calls required due to equipment failure.  Service billings will continue to fluctuate from period to period based upon equipment failure, whether through operator error or wear and tear, and pre-scheduled service activities such as equipment relocation.  Service revenue attributable to contract revenues is recognized at the time of performance and not at the time of contract execution.

 

4
 

 

 Gross Profit

 

Gross profit on system revenue during the three months ended March 31, 2011, was $219,066 compared to $0 for the same period in 2012.  Gross profit on the sale of consumables, component parts, service billings and amortization of maintenance contracts during the three months ended March 31, 2012, was $54,983 compared to $68,642 for the same period in 2011.

 

 Operating Expenses

 

Total operating expenses for the three months ended March 31, 2012, was $303,988, compared with $941,686 for the same period in 2011, a decrease of $637,698.  In the three months ended March 31, 2012, we recognized non-cash equity based compensation to service providers and employees of $4,625, as compared to $352,733 recorded as equity based compensation for the same period in 2011. In addition, the variance reflects a decrease in professional fees and rent, marketing and travel expenses.

 

Interest and Other Income

 

Interest and other income for the three months ended March 31, 2012, was $0 compared to $88 for the same period in 2011.

 

Derivative liability

 

Change in fair value of derivative liability was a net loss of $56,835 for the three months ended March 31, 2012 as compared to a net loss of $189,165 for the same period last year.

 

Interest expense

 

Interest expense and amortization for the three months ended March 31, 2012, was $93,240, compared with $697,708 for the same period in 2011.  During the three months ended March 31, 2012, we recognized non-cash amortization expense, of convertible note debt discount, amounting to $86,952, compared to $469,681 for the same period in 2011.

 

Net Income (loss)

 

Net loss for the three month period ended March 31, 2012, was $399,080, compared to a loss of $1,540,763 for the same period in 2011.

 

Liquidity and Capital Resources

 

The Company’s cash on hand and working capital as of March 31, 2011, and December 31, 2011, are as follows:

 

   March 31,   December 31, 
   2012   2011 
         
Cash on hand  $12,914   $26,009 
           
Working capital (deficit)  $(1,506,188)  $(1,317,482)

 

5
 

 

Under current conditions, the Company anticipates purchasing approximately $3,000 in additional fixed assets in 2012.  Net cash used by operating activities totaled $73,095 for the three months ended March 31, 2012.

 

Our accounts receivable balance may have dramatic swings from one period to another depending upon the timing and the amount of milestone billings included in the balance at the end of any accounting period.  There are three milestone billings representing a percentage of the contract value for each installment and our payment terms are “upon receipt.”  Receivable balances are typically paid within 15 days of the invoice date.  Billings for maintenance contracts and consumables are due within 45 days and are more numerous but much smaller in value than milestone billings.  We review our outstanding receivable balances on a regular basis to ensure that the allowance for bad debt is adequate.  Due to the varying nature in the timing and amounts of the receivable balances as noted above, the change in the allowance for doubtful account will not necessarily correlate with the increase or decrease in the accounts receivable balance.  The accounts receivable balance as of March 31, 2012, was $95,057 net of an allowance of $24,098, a decrease of $75,528 from year ended December 31, 2011.

 

Our inventory balance may have dramatic swings from one period to another depending upon the expected installation date of our MedClean systems and our accounts payable balances can have similar swings depending on payment terms and any volume purchases or discounts we may take advantage of from time to time.  During the three months ended March 31, 2012, the Company decreased its inventory on hand by $32,741 to $369,937.

 

During the three months ended March 31, 2012, we received $60,000 from our equity line of credit, whereby we issued an aggregate of 95,650,023 shares of our common stock as part of the put agreement.

 

To supplement its cash resources, the Company has been pursuing a number of alternative financing arrangements with various investment entities.  We are currently looking to secure additional working capital to provide the necessary funds for us to execute our business plan through various sources, including bank facilities, bridge loans and equity offerings.  However, we continue to incur significant operating losses and the resultant reduction of our cash position.  We cannot assure that we will be able to obtain additional funding, and the lack thereof would have a material adverse impact on our business.  Moreover, any equity funding could be substantially dilutive to existing stockholders.  The aforementioned factors raise substantial doubt about our ability to continue as a going concern.  In the event the Company is unable to continue as a going concern it may pursue a number of different options, including, but not limited to, filing for protection under the federal bankruptcy code.

 

Off-Balance Sheet Arrangements

 

As of March 31, 2012, the Company had no off-balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

We do not hold any derivative instruments and do not engage in any hedging activities.

 

Item 4. Controls and Procedures.

 

(a) Evaluation of Disclosure Controls and Procedures

 

Pursuant to Rule 13a- 15(b) under the Exchange Act, the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Principal Executive Officer (“PEO”) and Principal Financial Officer (“PFO”), of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company’s PEO and PFO concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s PEO and PFO, as appropriate, to allow timely decisions regarding required disclosure.

 

6
 

 

(b) Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations.  There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

Item 1A. Risk Factors.

 

Other than the risk factor below there have been no material changes from the risk factors previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed with the SEC on May 15, 2012.

 

OUR SHARES OF COMMON STOCK ARE NO LONGER ELIGIBLE TO BE TRADED ELECTRONICALLY. AS A RESULT, BROKERAGE FIRMS MAY BE UNWILLING TO TRADE WITH US.

 

If an issuer is not "DTC-eligible," then its shares cannot be electronically transferred between brokerage accounts, which, based on the realities of the marketplace as it exists today (particularly the OTCBB) means that shares of a company will not be traded (technically the shares can be traded manually between accounts, but this takes days and is not a realistic option for companies relying on broker dealers for stock transactions like all companies on the OTCBB). While DTC-eligibility is not a requirement to trade on the OTCBB, it is a necessity to process trades on the OTCBB if a company's stock is going to track with any volume. Currently, our shares are not DTC-eligibile. There are no assurances that our shares will again become DTC-eligible or, if they do, how long it will take.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

There were no unregistered sales of the Company’s equity securities during the quarter ended March 31, 2012, that were not otherwise disclosed on a Form 8-K.

 

Item 3. Defaults upon Senior Securities.

 

There has been no default in the payment of principal, interest, sinking or purchase fund installment, or any other material default not cured within 30 days, with respect to any indebtedness of the Company.

 

Item 4. Mining Safety Disclosures.

 

Not applicable

 

Item 5. Other Information.

 

There is no other information required to be disclosed under this item which was not previously disclosed.

 

7
 

 

Item 6. Exhibits.

 

Exhibit

No.

  Description
31.1   Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).*
     
31.2   Certification by the Principal Accounting Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).*
     
32.1   Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
     
32.2   Certification by the Principal Accounting Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

__________

* Filed herewith

 

8
 

 

 SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  MEDCLEAN TECHNOLOGIES, INC.  
       
Date: May 21, 2012 By: /s/ David Laky  
    Name: David Laky  
   

Title: Chief Executive Officer

          (Principal Executive Officer)

 
       
Date: May 21, 2012 By: /s/ Cheryl K. Sadowski  
    Name: Cheryl K. Sadowski  
   

Title: Chief Financial Officer

          (Principal Financial Officer)

          (Principal Accounting Officer)

 

 

9